Intec Pharma (NTEC) Given a $15.00 Price Target at Oppenheimer

Oppenheimer set a $15.00 price objective on Intec Pharma (NASDAQ:NTEC) in a report published on Monday morning. The firm currently has a buy rating on the biotechnology company’s stock.

NTEC has been the topic of several other research reports. Maxim Group set a $8.00 price target on shares of Intec Pharma and gave the stock a buy rating in a research note on Friday, November 17th. Zacks Investment Research upgraded shares of Intec Pharma from a sell rating to a hold rating in a research note on Friday, September 22nd. CIBC reiterated an outperform rating and set a $15.00 price target (up previously from $10.00) on shares of Intec Pharma in a research note on Thursday, September 21st. Finally, ValuEngine cut shares of Intec Pharma from a hold rating to a sell rating in a research note on Thursday, November 16th. One investment analyst has rated the stock with a sell rating and five have assigned a buy rating to the stock. The company currently has a consensus rating of Buy and a consensus target price of $10.70.

Shares of Intec Pharma (NASDAQ:NTEC) traded up $0.10 during trading on Monday, hitting $5.10. 62,900 shares of the stock traded hands, compared to its average volume of 49,593. Intec Pharma has a 1-year low of $4.20 and a 1-year high of $9.80.

Several institutional investors and hedge funds have recently added to or reduced their stakes in NTEC. Migdal Insurance & Financial Holdings Ltd. lifted its stake in shares of Intec Pharma by 5.0% during the 2nd quarter. Migdal Insurance & Financial Holdings Ltd. now owns 522,200 shares of the biotechnology company’s stock valued at $2,977,000 after buying an additional 25,000 shares in the last quarter. Caxton Corp bought a new stake in Intec Pharma in the 3rd quarter valued at $681,000. Sectoral Asset Management Inc bought a new stake in Intec Pharma in the 3rd quarter valued at $3,177,000. Finally, Pura Vida Investments LLC bought a new stake in Intec Pharma in the 3rd quarter valued at $895,000. Institutional investors own 40.16% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Intec Pharma (NTEC) Given a $15.00 Price Target at Oppenheimer” was published by Community Financial News and is the sole property of of Community Financial News. If you are reading this piece on another website, it was illegally stolen and reposted in violation of United States & international copyright and trademark law. The correct version of this piece can be viewed at https://www.com-unik.info/2017/12/22/intec-pharma-ntec-given-a-15-00-price-target-at-oppenheimer.html.

About Intec Pharma

Intec Pharma Ltd is an Israel-based drug development company. It is a development stage biopharmaceutical company that develops formulations of drugs using its proprietary gastric retention technology, the Accordion Pill. The Accordion Pill, a novel gastro-retentive delivery system, improves the pharmacokinetics and pharmacodynamics of various drugs.

Receive News & Ratings for Intec Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intec Pharma and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit